Biomarkers of Alzheimer’s disease (AD) may have prognostic value in early stages of Parkinson’s disease (PD). These biomarkers may be useful for prediction of cognition, motor and autonomic function in PD.
Why this matters
While α-synuclein (aSyn) Lewy pathology is a hallmark of PD, there is also a varying severity of mixed AD-associated amyloid-beta (Aβ42) plaques and tau tangles found in the brains of patients with PD at autopsy. Identifying markers of AD pathology during the patient’s life may have prognostic implications to guide patient selection for clinical trials.